Trial reportDisease markers2021
Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children.
Trial report in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Pooled it
- The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Association between the TyG/HDL-C ratio and non-alcoholic fatty liver disease: a single-centre retrospective study.BMC gastroenterology · 2026Article
- Elevated Triglyceride-Glucose Index Is Associated With Insulin Resistance, Metabolic Syndrome Components, Nonalcoholic Fatty Liver Disease, and Adverse Pregnancy Outcomes in Chinese Women With Polycystic Ovary Syndrome.Clinical endocrinology · 2025Article
- Clinical Features and Plasma Metabolites Analysis in Obese Chinese Children With Nonalcoholic Fatty Liver Disease.Journal of the Endocrine Society · 2025Article
- A new perspective on non-invasive diagnosis of non- alcoholic fatty liver disease: evidence integration of inflammatory and metabolic biomarkers based on a scoping review.Frontiers in endocrinology · 2025Article
- Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver DiseaseJournal of clinical research in pediatric endocrinology · 2024Article
- Biochemical and Anthropometric Indices of Insulin Resistance in Obese and Overweight Children with Metabolic Dysfunction-Associated Fatty Liver Disease.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Evaluation of the ability of insulin resistance and lipid-related indices to predict the presence of NAFLD in obese adolescents.Lipids in health and disease · 2024Article
- Association Between Triglyceride-Glucose Index and Lung Function Parameters in the General Population Undergoing Health Examinations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults.BMC gastroenterology · 2023Article
- Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.Metabolites · 2023Review
- HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population.The Journal of international medical research · 2023Observational
- Triglyceride-glucose index and cervical vascular function: outpatient-based cohort study.BMC endocrine disorders · 2023Article
- Dynamic NLR and PLR in Predicting COVID-19 Severity: A Retrospective Cohort Study.Infectious diseases and therapy · 2023Article
- What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).Journal of clinical medicine · 2023Review
- Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth.Biology · 2022Article
- Study on Syndrome Intervention of Nonalcoholic Fatty Liver Disease from the Perspective of Deficiency and Excess.Journal of healthcare engineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of NAFLD requires a liver biopsy, which is difficult in children. This study explored the diagnostic value of pentraxin 3 (PTX-3) and the triglyceride-glucose (TyG) index for NAFLD in children.
methodsSixty-eight children with NAFLD were selected as study subjects, and 68 healthy children enrolled during the same period served as controls. The TyG index was calculated, serum PTX-3 expression was detected by enzyme-linked immunosorbent assay, and the correlations between PTX-3 or the TyG index and clinical and biochemical indicators were analyzed. A receiver operating characteristics curve analysis and area under the curve (AUC) were used to evaluate diagnostic accuracy.
resultsSerum PTX-3 level and the TyG index of the NAFLD patients were significantly higher than those of the healthy controls (
conclusionPTX-3 and the TyG index are novel diagnostic biomarkers for NAFLD, as they effectively improved the diagnostic accuracy for NAFLD when combined with ALT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.